Alcami, a provider of custom development and manufacturing services, has finalized manufacturing and quality agreements with Solasia Pharma, K.K. for the clinical supply manufacture of the active pharmaceutical ingredient (API) darinaparsin, a mitochondrial-targeted agent developed for the treatment of various hematologic and solid cancers. 

Process development for darinaparsin and clinical manufacturing will begin in 4Q17 at Alcami’s new highly potent API suites at its Center of Excellence facility in Germantown, WI.

Solasia, based in Japan, is a specialty pharmaceutical company developing oncology medicines. In March 2011, Solasia acquired the rights to darinaparsin from ZIOPHARM Oncology, Inc. for the potential treatment of Peripheral T-Cell Lymphoma (PTCL). The drug is currently in Phase II trials in Asia. 

“We are pleased to entrust Alcami with this project,” said Mr. Yoshihiro Arai, president and chief executive officer of Solasia Pharma, K.K. “Finding a responsible partner for the development and manufacturing of our API was a significant step in our clinical program.”
  
“We are extremely grateful for the opportunity to partner with Solasia as the trusted supplier of darinaparsin. Our relationship is an excellent example of Alcami’s dedication to delivering reliable and high quality medicines across the globe. As we continue to grow our established business in Japan, we look forward to supporting Solasia for its future clinical and commercial success,” said Syed T. Husain, chief commercial officer of Alcami.